Immune modulation of inflammatory conditions: Regulatory T cells for treatment of GvHD

Immunologic Research

Volumn 53, Issue 1-3, 2012, Pages 200-212

  Haase, Doreen ^a   Starke, Mireille ^a   Puan, Kia Joo ^a   Lai, Tuck Siong ^a   Rotzschke, Olaf ^a  

^a AGENCY FOR SCIENCE   (Singapore)

Author keywords

Adoptive cell therapy; CD39; CD49d; Cell isolation; Clinical trial; Rapamycin; Treg; TREM

Indexed keywords

ALPHA4 INTEGRIN; CD39 ANTIGEN; CHEMOKINE RECEPTOR CCR6; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 7 RECEPTOR;

ADOPTIVE TRANSFER; ANTIGEN EXPRESSION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; EFFECTOR CELL; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY DISEASE; MEMORY T LYMPHOCYTE; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; STEM CELL TRANSPLANTATION; TH17 CELL; UNSPECIFIED SIDE EFFECT;

ANIMALS; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; GRAFT VS HOST DISEASE; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOMODULATION; IMMUNOTHERAPY, ADOPTIVE; INFLAMMATION; MICE; STEM CELL TRANSPLANTATION; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 84866736535     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-012-8267-9     Document Type: Article

References (113)

1. Sullivan KM, Deeg HJ, Sanders J, Klosterman A, Amos D, Shulman H, Sale G, Martin P, Witherspoon R, Appelbaum F, et al. Hyperacute graft-v-host disease in patients not given immunosuppression after allogeneic marrow transplantation. Blood. 1986;67(4):1172-5.
2. Schroeder MA, DiPersio JF. Mouse models of graft-versus-host disease: advances and limitations. Dis Model Mech. 2011;4(3):318-33.
3. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, Schubert M, Schultz K, Shulman H, Turner M, Vogelsang G, Flowers ME. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versushost disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transpl. 2005;11(12):945-56.
4. Schaffer JV. The changing face of graft-versus-host disease. Semin Cutan Med Surg. 2006;25(4):190-200.
5. Kawase T, Morishima Y, Matsuo K, Kashiwase K, Inoko H, Saji H, Kato S, Juji T, Kodera Y, Sasazuki T. High-risk HLA allele mismatch combinations responsible for severe acute graft-versus- host disease and implication for its molecular mechanism. Blood. 2007;110(7):2235-41.
6. Sasazuki T, Juji T, Morishima Y, Kinukawa N, Kashiwabara H, Inoko H, Yoshida T, Kimura A, Akaza T, Kamikawaji N, Kodera Y, Takaku F. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program. N Engl J Med. 1998;339(17):1177-85.
7. Deeg HJ, Lin D, Leisenring W, Boeckh M, Anasetti C, Appelbaum FR, Chauncey TR, Doney K, Flowers M, Martin P, Nash R, Schoch G, Sullivan KM, Witherspoon RP, Storb R. Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial. Blood. 1997;89(10):3880-7.
8. Alyea EP, Li S, Kim HT, Cutler C, Ho V, Soiffer RJ, Antin JH. Sirolimus, tacrolimus, and low-dose methotrexate as graft-versushost disease prophylaxis in related and unrelated donor reducedintensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transpl. 2008;14(8):920-6.
9. Schleuning M, Judith D, Jedlickova Z, Stubig T, Heshmat M, Baurmann H, Schwerdtfeger R. Calcineurin inhibitor-free GVHD prophylaxis with sirolimus, mycophenolate mofetil and ATG in Allo-SCT for leukemia patients with high relapse risk: an observational cohort study. Bone Marrow Transpl. 2009;43(9):717-23.
10. Bram RJ, Hung DT, Martin PK, Schreiber SL, Crabtree GR. Identification of the immunophilins capable of mediating inhibition of signal transduction by cyclosporin A and FK506: roles of calcineurin binding and cellular location. Mol Cell Biol. 1993;13(8):4760-9.
11. Thomson AW. FK-506 enters the clinic. Immunol Today. 1990;11(2):35-6.
12. Martin PJ, Storer BE, Rowley SD, Flowers ME, Lee SJ, Carpenter PA, Wingard JR, Shaughnessy PJ, DeVetten MP, Jagasia M, Fay JW, van Besien K, Gupta V, Kitko C, Johnston LJ, Maziarz RT, Arora M, Jacobson PA, Weisdorf D. Evaluation of mycophenolate mofetil for initial treatment of chronic graftversus- host disease. Blood. 2009;113(21):5074-82.
13. Johnston L, Florek M, Armstrong R, McCune JS, Arai S, Brown J, Laport G, Lowsky R, Miklos D, Shizuru J, Sheehan K, Lavori P, Negrin R. Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative, matched-related donor hematopoietic cell transplantation. Bone Marrow Transpl. 2011. doi: 10.1038/bmt.2011.104.
14. Cutler C, Antin JH. Sirolimus immunosuppression for graftversus- host disease prophylaxis and therapy: an update. Curr Opin Hematol. 2010;17(6):500-4.
15. Battaglia M, Stabilini A, Migliavacca B, Horejs-Hoeck J, Kaupper T, Roncarolo MG. Rapamycin promotes expansion of functional CD4?CD25?FOXP3? regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol. 2006;177(12):8338-47.
16. Lopez M, Clarkson MR, Albin M, Sayegh MH, Najafian N. A novel mechanism of action for anti-thymocyte globulin: induction of CD4?CD25?Foxp3? regulatory T cells. J Am Soc Nephrol. 2006;17(10):2844-53.
17. Feng X, Kajigaya S, Solomou EE, Keyvanfar K, Xu X, Raghavachari N, Munson PJ, Herndon TM, Chen J, Young NS. Rabbit ATG but not horse ATG promotes expansion of functional CD4?CD25highFOXP3? regulatory T cells in vitro. Blood. 2008;111(7):3675-83.
18. Knop S, Hebart H, Gscheidle H, Holler E, Kolb HJ, Niederwieser D, Einsele H. OKT3 muromonab as second-line and subsequent treatment in recipients of stem cell allografts with steroid-resistant acute graft-versus-host disease. Bone Marrow Transpl. 2005;36(9):831-7.
19. Gleixner B, Kolb HJ, Holler E, Liesenfeld S, Riedner C, Hiller E, Seeber C, Kempeni J, Moller A, Knabe H, et al. Treatment of aGVHD with OKT3: clinical outcome and side-effects associated with release of TNF alpha. Bone Marrow Transpl. 1991;8(2):93-8.
20. Martin PJ, Shulman HM, Schubach WH, Hansen JA, Fefer A, Miller G, Thomas ED. Fatal Epstein-Barr-virus-associated proliferation of donor B cells after treatment of acute graft-versushost disease with a murine anti-T-cell antibody. Ann Intern Med. 1984;101(3):310-5.
21. Carpenter PA, Lowder J, Johnston L, Frangoul H, Khoury H, Parker P, Jerome KR, McCune JS, Storer B, Martin P, Appelbaum F, Abonour R, Westervelt P, Anasetti C. A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transpl. 2005;11(6):465-71.
22. Bordigoni P, Dimicoli S, Clement L, Baumann C, Salmon A, Witz F, Feugier P. Daclizumab, an efficient treatment for steroid- refractory acute graft-versus-host disease. Br J Haematol. 2006;135(3):382-5.
23. Przepiorka D, Kernan NA, Ippoliti C, Papadopoulos EB, Giralt S, Khouri I, Lu JG, Gajewski J, Durett A, Cleary K, Champlin R, Andersson BS, Light S. Daclizumab, a humanized antiinterleukin- 2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood. 2000;95(1):83-9.
24. Anasetti C, Hansen JA, Waldmann TA, Appelbaum FR, Davis J, Deeg HJ, Doney K, Martin PJ, Nash R, Storb R, et al. Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood. 1994;84(4):1320-7.
25. Massenkeil G, Rackwitz S, Genvresse I, Rosen O, Dorken B, Arnold R. Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Bone Marrow Transpl. 2002;30(12):899-903.
26. Schmidt-Hieber M, Fietz T, Knauf W, Uharek L, Hopfenmuller W, Thiel E, Blau IW. Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versushost disease. Br J Haematol. 2005;130(4):568-74.
27. Solstad T, Bains SJ, Landskron J, Aandahl EM, Thiede B, Tasken K, Torgersen KM. CD147 (Basigin/Emmprin) identifies FoxP3?CD45RO?CTLA4?-activated human regulatory T cells. Blood. 2011;118(19):5141-51.
28. Macmillan ML, Couriel D, Weisdorf DJ, Schwab G, Havrilla N, Fleming TR, Huang S, Roskos L, Slavin S, Shadduck RK, Dipersio J, Territo M, Pavletic S, Linker C, Heslop HE, Joachim Deeg H, Blazar BR. A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. Blood. 2007;109(6):2657-62.
29. Hale G, Jacobs P, Wood L, Fibbe WE, Barge R, Novitzky N, Toit C, Abrahams L, Thomas V, Bunjes D, Duncker C, Wiesneth M, Selleslag D, Hidajat M, Starobinski M, Bird P, Waldmann H. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells. Bone Marrow Transpl. 2000;26(1):69-76.
30. Levine JE, Paczesny S, Mineishi S, Braun T, Choi SW, Hutchinson RJ, Jones D, Khaled Y, Kitko CL, Bickley D, Krijanovski O, Reddy P, Yanik G, Ferrara JL. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood. 2008;111(4):2470-5.
31. Patriarca F, SperottoA,Damiani D,MorrealeG,Bonifazi F, Olivieri A, Ciceri F, Milone G, Cesaro S, Bandini G, Dini G, Corradini P, Fanin R. Infliximab treatment for steroid-refractory acute graft-versus- host disease. Haematologica. 2004;89(11):1352-9.
32. Tantravahi J, Womer KL, Kaplan B. Why hasn't eliminating acute rejection improved graft survival? Annu Rev Med. 2007;58:369-85.
33. Selzner N, Grant DR, Shalev I, Levy GA. The immunosuppressive pipeline: meeting unmet needs in liver transplantation. Liver Transpl. 2010;16(12):1359-72.
34. Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, Gerdoni E, Giunti D, Ceravolo A, Cazzanti F, Frassoni F, Mancardi G, Uccelli A. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood. 2005;106(5):1755-61.
35. Sato K, Ozaki K, Mori M, Muroi K, Ozawa K. Mesenchymal stromal cells for graft-versus-host disease : basic aspects and clinical outcomes. J Clin Exp Hematop. 2010;50(2):79-89.
36. Lazarus HM, Koc ON, Devine SM, Curtin P, Maziarz RT, Holland HK, Shpall EJ, McCarthy P, Atkinson K, Cooper BW, Gerson SL, Laughlin MJ, Loberiza FR Jr, Moseley AB, Bacigalupo A. Cotransplantation of HLA-identical sibling cultureexpanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transpl. 2005;11(5):389-98.
37. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B,BernardoME,Remberger M,DiniG, Egeler RM, Bacigalupo A, Fibbe W, Ringden O.Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008;371(9624):1579- 86.
38. Allison M. Genzyme backs Osiris, despite Prochymal flop. Nat Biotechnol. 2009;27(11):966-7.
39. Shook DR, Campana D. Natural killer cell engineering for cellular therapy of cancer. Tissue Antigens. 2011;78(6):409-15.
40. Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA, JonsonAL, Panoskaltsis-Mortari A, Curtsinger J, McKenna D, Dusenbery K, Bliss R, Downs LS, Miller JS. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy. 2011;13(1):98-107.
41. Bachanova V, Burns LJ, McKenna DH, Curtsinger J, Panoskaltsis- Mortari A, Lindgren BR, Cooley S, Weisdorf D, Miller JS. Allogeneic natural killer cells for refractory lymphoma. Cancer Immunol Immunother. 2010;59(11):1739-44.
42. Yang J, FanH,Hao J, RenY,ChenL, LiG,Xie R, Yang Y, Qian K, LiuM. Amelioration of acute graft-versus-host disease by adoptive transfer of ex vivo expanded human cord blood CD4?CD25? forkhead box protein 3? regulatory T cells is associated with the polarization of Treg/Th17 balance in a mouse model. Transfusion. 2011. doi:10.1111/j.1537-2995.2011.03448.x.
43. Olson JA, Leveson-Gower DB, Gill S, Baker J, Beilhack A, Negrin RS. NK cells mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects. Blood. 2010;115(21):4293-301.
44. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299(5609):1057-61.
45. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4?CD25? regulatory T cells. Nat Immunol. 2003;4(4):330-6.
46. Thornton AM, Shevach EM. Suppressor effector function of CD4?CD25? immunoregulatory T cells is antigen nonspecific. J Immunol. 2000;164(1):183-90.
47. Smyth MJ, Teng MW, Swann J, Kyparissoudis K, Godfrey DI, Hayakawa Y. CD4?CD25? T regulatory cells suppress NK cellmediated immunotherapy of cancer. J Immunol. 2006;176(3): 1582-7.
48. Lim HW, Hillsamer P, Banham AH, Kim CH. Cutting edge: direct suppression of B cells by CD4?CD25? regulatory T cells. J Immunol. 2005;175(7):4180-3.
49. Kleinewietfeld M, Puentes F, Borsellino G, Battistini L, Rotzschke O, Falk K. CCR6 expression defines regulatory effector/ memory-like cells within the CD25(?)CD4? T-cell subset. Blood. 2005;105(7):2877-86.
50. Camara NO, Sebille F, Lechler RI. Human CD4?CD25? regulatory cells have marked and sustained effects on CD8 ? T cell activation. Eur J Immunol. 2003;33(12):3473-83.
51. Wildin RS, Ramsdell F, Peake J, Faravelli F, Casanova JL, Buist N, Levy-Lahad E, Mazzella M, Goulet O, Perroni L, Bricarelli FD, Byrne G, McEuen M, Proll S, Appleby M, Brunkow ME. X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat Genet. 2001;27(1):18-20.
52. Chatenoud L. Natural and induced T CD4?CD25?FOXP3? regulatory T cells. Methods Mol Biol. 2011;677:3-13.
53. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155(3):1151-64.
54. Modigliani Y, Coutinho A, Pereira P, LeDouarinN, Thomas-Vaslin V, Burlen-Defranoux O, Salaun J, Bandeira A. Establishment of tissue-specific tolerance is driven by regulatory T cells selected by thymic epithelium. Eur J Immunol. 1996;26(8):1807-15.
55. Floess S, Freyer J, Siewert C, Baron U, Olek S, Polansky J, Schlawe K, Chang HD, Bopp T, Schmitt E, Klein-Hessling S, Serfling E, Hamann A, Huehn J. Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol. 2007;5(2):e38.
56. Huehn J, Polansky JK, Hamann A. Epigenetic control of FOXP3 expression: the key to a stable regulatory T-cell lineage? Nat Rev Immunol. 2009;9(2):83-9.
57. Zhou L, Chong MM, Littman DR. Plasticity of CD4? T cell lineage differentiation. Immunity. 2009;30(5):646-55.
58. Sallusto F, Lenig D, Mackay CR, Lanzavecchia A. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med. 1998;187(6):875-83.
59. Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, Mazzinghi B, Parente E, Fili L, Ferri S, Frosali F, Giudici F, Romagnani P, Parronchi P, Tonelli F, Maggi E, Romagnani S. Phenotypic and functional features of human Th17 cells. J Exp Med. 2007;204(8):1849-61.
60. Iellem A, Mariani M, Lang R, Recalde H, Panina-Bordignon P, Sinigaglia F, D'Ambrosio D. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(?)CD25(?) regulatory T cells. J Exp Med. 2001;194(6):847-53.
61. Oswald-Richter K, Grill SM, Shariat N, Leelawong M, Sundrud MS, Haas DW, Unutmaz D. HIV infection of naturally occurring and genetically reprogrammed human regulatory T-cells. PLoS Biol. 2004;2(7):E198.
62. O'Garra A, Vieira P. Regulatory T cells and mechanisms of immune system control. Nat Med. 2004;10(8):801-5.
63. Ermann J, Szanya V, Ford GS, Paragas V, Fathman CG, Lejon K. CD4(?)CD25(?) T cells facilitate the induction of T cell anergy. J Immunol. 2001;167(8):4271-5.
64. Nakamura K, Kitani A, Strober W. Cell contact-dependent immunosuppression by CD4(?)CD25(?) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med. 2001;194(5):629-44.
65. Tang Q, Bluestone JA. The Foxp3? regulatory T cell: a jack of all trades, master of regulation. Nat Immunol. 2008;9(3): 239-44.
66. Matzinger P. The danger model: a renewed sense of self. Science. 2002;296(5566):301-5.
67. Beigi RD, Kertesy SB, Aquilina G, Dubyak GR. Oxidized ATP (oATP) attenuates proinflammatory signaling via P2 receptorindependent mechanisms. Br J Pharmacol. 2003;140(3):507-19.
68. Wilkin F, Duhant X, Bruyns C, Suarez-Huerta N, Boeynaems JM, Robaye B. The P2Y11 receptor mediates the ATP-induced maturation of human monocyte-derived dendritic cells. J Immunol. 2001;166(12):7172-7.
69. Canaday DH, Beigi R, Silver RF, Harding CV, Boom WH, Dubyak GR. ATP and control of intracellular growth of mycobacteria by T cells. Infect Immun. 2002;70(11):6456-9.
70. la Sala A, Ferrari D, Corinti S, Cavani A, Di Virgilio F, Girolomoni G. Extracellular ATP induces a distorted maturation of dendritic cells and inhibits their capacity to initiate Th1 responses. J Immunol. 2001;166(3):1611-7.
71. Salcido-Ochoa F, Tsang J, Tam P, Falk K, Rotzschke O. Regulatory T cells in transplantation: does extracellular adenosine triphosphate metabolism through CD39 play a crucial role? Transpl Rev (Orlando). 2010;24(2):52-66.
72. Borsellino G, Kleinewietfeld M, Di Mitri D, Sternjak A, Diamantini A, Giometto R, Hopner S, Centonze D, Bernardi G, Dell'Acqua ML, Rossini PM, Battistini L, Rotzschke O, Falk K. Expression of ectonucleotidase CD39 by Foxp3? Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood. 2007;110(4):1225-32.
73. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, Chen JF, Enjyoji K, Linden J, Oukka M, Kuchroo VK, Strom TB, Robson SC. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med. 2007;204(6):1257-65.
74. Kaczmarek E, Koziak K, Sevigny J, Siegel JB, Anrather J, Beaudoin AR, Bach FH, Robson SC. Identification and characterization of CD39/vascular ATP diphosphohydrolase. J Biol Chem. 1996;271(51):33116-22.
75. Mariathasan S, Weiss DS, Newton K, McBride J, O'Rourke K, Roose-Girma M, Lee WP, Weinrauch Y, Monack DM, Dixit VM. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature. 2006;440(7081):228-32.
76. Aswad F, Kawamura H, Dennert G. High sensitivity of CD4?CD25? regulatory T cells to extracellular metabolites nicotinamide adenine dinucleotide and ATP: a role for P2X7 receptors. J Immunol. 2005;175(5):3075-83.
77. Resta R, Yamashita Y, Thompson LF. Ecto-enzyme and signaling functions of lymphocyte CD73. Immunol Rev. 1998;161:95-109.
78. Zhang N, Yang D, Dong H, Chen Q, Dimitrova DI, Rogers TJ, Sitkovsky M, Oppenheim JJ. Adenosine A2a receptors induce heterologous desensitization of chemokine receptors. Blood. 2006;108(1):38-44.
79. Erdmann AA, Gao ZG, Jung U, Foley J, Borenstein T, Jacobson KA, Fowler DH. Activation of Th1 and Tc1 cell adenosine A2A receptors directly inhibits IL-2 secretion in vitro and IL-2-driven expansion in vivo. Blood. 2005;105(12):4707-14.
80. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(?)CD25(?) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med. 2002;196(3):389-99.
81. Miura Y, Thoburn CJ, Bright EC, Phelps ML, Shin T, Matsui EC, Matsui WH, Arai S, Fuchs EJ, Vogelsang GB, Jones RJ, Hess AD. Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood. 2004;104(7):2187-93.
82. Pflumio F, Lapidot T, Murdoch B, Patterson B, Dick JE. Engraftment of human lymphoid cells into newborn SCID mice leads to graft-versus-host disease. Int Immunol. 1993;5(12): 1509-22.
83. Lowry PA, Shultz LD, Greiner DL, Hesselton RM, Kittler EL, Tiarks CY, Rao SS, Reilly J, Leif JH, Ramshaw H, Stewart FM, Quesenberry PJ. Improved engraftment of human cord blood stem cells in NOD/LtSz-scid/scid mice after irradiation or multiple-day injections into unirradiated recipients. Biol Blood Marrow Transpl. 1996;2(1):15-23.
84. Verlinden SF, Mulder AH, de Leeuw JP, van Bekkum DW. T lymphocytes determine the development of xeno GVHD and of human hemopoiesis in NOD/SCID mice following human umbilical cord blood transplantation. Stem Cells. 1998;16(Suppl 1):205-17.
85. Riley JL, June CH, Blazar BR. Human T regulatory cell therapy: take a billion or so and call me in the morning. Immunity. 2009;30(5):656-65.
86. Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4(?)CD25(?) immune regulatory cells inhibits graft-versus-host disease lethality. Blood. 2002;99(10): 3493-9.
87. Joffre O, Gorsse N, Romagnoli P, Hudrisier D, van Meerwijk JP. Induction of antigen-specific tolerance to bone marrow allografts with CD4?CD25? T lymphocytes. Blood. 2004;103(11):4216-21.
88. van Rijn RS, Simonetti ER, Hagenbeek A,HogenesMC, deWeger RA, Canninga-van Dijk MR, Weijer K, Spits H, Storm G, van Bloois L, Rijkers G, Martens AC, Ebeling SB. A new xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2-/- gammac-/- double-mutant mice. Blood. 2003;102(7):2522-31.
89. Mutis T, van Rijn RS, Simonetti ER, Aarts-Riemens T, Emmelot ME, van Bloois L, Martens A, Verdonck LF, Ebeling SB. Human regulatory T cells control xenogeneic graft-versus-host disease induced by autologous T cells in RAG2-/-gammac-/- immunodeficient mice. Clin Cancer Res. 2006;12(18): 5520-5.
90. Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K, Ueyama Y, Koyanagi Y, Sugamura K, Tsuji K, Heike T, Nakahata T. NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood. 2002;100(9):3175-82.
91. Shultz LD, Lyons BL, Burzenski LM, Gott B, Chen X, Chaleff S, Kotb M, Gillies SD, King M, Mangada J, Greiner DL, Handgretinger R. Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R gamma null mice engrafted with mobilized human hemopoietic stem cells. J Immunol. 2005;174(10):6477-89.
92. Semple K, Yu Y, Wang D, Anasetti C, Yu XZ. Efficient and selective prevention of GVHD by antigen-specific induced Tregs via linked-suppression in mice. Biol Blood Marrow Transpl. 2011;17(3):309-18.
93. Xia G, Truitt RL, Johnson BD. Graft-versus-leukemia and graftversus- host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras. Biol Blood Marrow Transpl. 2006;12(4):397-407.
94. Kleinewietfeld M, Starke M, Di Mitri D, Borsellino G, Battistini L, Rotzschke O, Falk K. CD49d provides access to "untouched" human Foxp3? Treg free of contaminating effector cells. Blood. 2009;113(4):827-36.
95. Hoffmann P, Boeld TJ, Eder R, Albrecht J, Doser K, Piseshka B, Dada A, NiemandC,Assenmacher M, Orso E,AndreesenR,Holler E, Edinger M. Isolation of CD4?CD25? regulatory T cells for clinical trials. Biol Blood Marrow Transplant. 2006;12(3):267-74.
96. Edinger M, Hoffmann P. Regulatory T cells in stem cell transplantation: strategies and first clinical experiences. Curr Opin Immunol. 2011;23(5):679-84.
97. Di IanniM, Falzetti F,Carotti A, TerenziA,Castellino F,Bonifacio E, Del Papa B, Zei T, Ostini RI, Cecchini D, Aloisi T, Perruccio K, Ruggeri L, Balucani C, Pierini A, Sportoletti P, Aristei C, Falini B, ReisnerY,Velardi A,Aversa F,MartelliMF. Tregs preventGVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood. 2011;117(14):3921-8.
98. Takahata Y, Nomura A, Takada H, Ohga S, Furuno K, Hikino S, Nakayama H, Sakaguchi S, Hara T. CD25?CD4? T cells in human cord blood: an immunoregulatory subset with naive phenotype and specific expression of forkhead box p3 (Foxp3) gene. Exp Hematol. 2004;32(7):622-9.
99. Figueroa-Tentori D, Querol S, Dodi IA, Madrigal A, Duggleby R. High purity and yield of natural Tregs from cord blood using a single step selection method. J Immunol Methods. 2008;339(2): 228-35.
100. Godfrey WR, Spoden DJ, Ge YG, Baker SR, Liu B, Levine BL, June CH, Blazar BR, Porter SB. Cord blood CD4(?)CD25(?)- derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function. Blood. 2005;105(2):750-8.
101. Brunstein CG, Miller JS, Cao Q, McKenna DH, Hippen KL, Curtsinger J, Defor T, Levine BL, June CH, Rubinstein P, McGlave PB, Blazar BR, Wagner JE. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood. 2011;117(3):1061-70.
102. Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A, Solomon M, Selby W, Alexander SI, Nanan R, Kelleher A. Fazekas de St Groth B. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med. 2006;203(7):1693-700.
103. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, Fazekas de St Groth B, Clayberger C, Soper DM, Ziegler SF, Bluestone JA. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4? T reg cells. J Exp Med. 2006;203(7):1701-11.
104. Trzonkowski P, Bieniaszewska M, Juscinska J, Dobyszuk A, Krzystyniak A, Marek N, Mysliwska J, Hellmann A. First-in-man clinical results of the treatment of patients with graft versus host disease with human ex vivo expanded CD4?CD25?CD127-T regulatory cells. Clin Immunol. 2009;133(1):22-6.
105. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899-910.
106. Putnam AL, Brusko TM, Lee MR, Liu W, Szot GL, Ghosh T, Atkinson MA, Bluestone JA. Expansion of human regulatory T-cells from patients with type 1 diabetes. Diabetes. 2009;58(3): 652-62.
107. Pahwa R, Jaggaiahgari S, Pahwa S, Inverardi L, Tzakis A, Ricordi C. Isolation and expansion of human natural T regulatory cells for cellular therapy. J Immunol Methods. 2010;363(1):67-79.
108. Hippen KL, Merkel SC, Schirm DK, Sieben CM, Sumstad D, Kadidlo DM, McKenna DH, Bromberg JS, Levine BL, Riley JL, June CH, Scheinberg P, Douek DC, Miller JS, Wagner JE, Blazar BR. Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity. Sci Transl Med. 2011;3(83):83ra41.
109. Zhou X, Bailey-Bucktrout SL, Jeker LT, Penaranda C, Martinez- Llordella M, Ashby M, Nakayama M, Rosenthal W, Bluestone JA. Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol. 2009;10(9):1000-7.
110. Komatsu N, Mariotti-Ferrandiz ME, Wang Y, Malissen B, Waldmann H, Hori S. Heterogeneity of natural Foxp3? T cells: a committed regulatory T-cell lineage and an uncommitted minor population retaining plasticity. Proc Natl Acad Sci USA. 2009;106(6):1903-8.
111. Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea EP III, Armand P, Cutler C, Ho VT, Treister NS, Bienfang DC, Prasad S, Tzachanis D, Joyce RM, Avigan DE, Antin JH, Ritz J, Soiffer RJ. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011;365(22): 2055-66.
112. Mandapathil M, Lang S, Gorelik E, Whiteside TL. Isolation of functional human regulatory T cells (Treg) from the peripheral blood based on the CD39 expression. J Immunol Methods. 2009;346(1-2):55-63.
113. Schuler PJ, Harasymczuk M, Schilling B, Lang S, Whiteside TL. Separation of human CD4?CD39? T cells by magnetic beads reveals two phenotypically and functionally different subsets. J Immunol Methods. 2011;369(1-2):59-68.